BUSINESS

Ono Chief, Honjo to Face Off in Opdivo Royalty Feud on September 2

August 3, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The first direct face-off between Ono Pharmaceutical President Gyo Sagara and Nobel laureate Tasuku Honjo in their legal battle over Opdivo (nivolumab) royalties has been set for September 2. At a trial held on July 30, representatives from both sides…

To read the full story

Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021

BUSINESS

Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
Japan Grants First-Ever Approval to iPSC-Based Therapies
March 6, 2026
Meiji Starts Japan PIII Trial of Rezurock for CLAD
March 6, 2026
Meiji Rolls Out Rezurock in Taiwan
March 6, 2026
Toray Out-Licenses Parkinson’s Drug to Immunis
March 6, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…